Inventor · disambiguated record
Laura Saunders
Also filed as: SAUNDERS LAURA
38 granted patents·12 pending applications·313 citations·filing 2013–2021
98Inventor score
Top patents by PatentIndex Score
50 records- 0198US11033634B2Light chain variable regionsABBVIE STEMCENTRX LLC·Filed 2019·Granted Jun 15, 2021·6 cites·16 claims
- 0297US9089615B2Anti-DLL3 antibodiesSTEM CENTRX INC·Filed 2014·Granted Jul 28, 2015·21 cites·30 claims
- 0397US8986972B2Nucleic acid encoding DLL3 antibodiesSTEM CENTRX INC·Filed 2014·Granted Mar 24, 2015·22 cites·30 claims
- 0496US9937268B2Anti-DLL3 antibody drug conjugates and methods of useABBVIE STEMCENTRX LLC·Filed 2017·Granted Apr 10, 2018·9 cites·30 claims
- 0596US9931421B2Methods of delivering DLL3 antibody drug conjugatesABBVIE STEMCENTRX LLC·Filed 2017·Granted Apr 3, 2018·9 cites·30 claims
- 0696US9931420B2Methods of making DLL3 antibody drug conjugatesABBVIE STEMCENTRX LLC·Filed 2017·Granted Apr 3, 2018·9 cites·30 claims
- 0796US9878053B2Methods of delivering DLL3 antibody drug conjugatesABBVIE STEMCENTRX LLC·Filed 2017·Granted Jan 30, 2018·9 cites·30 claims
- 0896US9867887B1Anti-DLL3 antibody drug conjugatesABBVIE STEMCENTRX LLC·Filed 2017·Granted Jan 16, 2018·9 cites·30 claims
- 0996US9861708B2Kits containing DLL3 antibody drug conjugatesABBVIE STEMCENTRX LLC·Filed 2017·Granted Jan 9, 2018·9 cites·30 claims
- 1096US9855343B2Anti-DLL3 antibody drug conjugatesABBVIE STEMCENTRX LLC·Filed 2017·Granted Jan 2, 2018·9 cites·30 claims
- 1196US9775916B1Anti-DLL3 antibody drug conjugates for treating cancerABBVIE STEMCENTRX LLC·Filed 2017·Granted Oct 3, 2017·9 cites·30 claims
- 1296US9770518B1Anti-DLL3 antibody drug conjugatesABBVIE STEMCENTRX LLC·Filed 2017·Granted Sep 26, 2017·9 cites·30 claims
- 1396US9764042B1Methods of making DLL3 antibody drug conjugatesABBVIE STEMCENTRX LLC·Filed 2017·Granted Sep 19, 2017·9 cites·30 claims
- 1496US9358304B1Methods of making DLL3 antibody drug conjugatesSTEMCENTRX INC·Filed 2016·Granted Jun 7, 2016·10 cites·30 claims
- 1596US9352051B1Kits containing DLL3 antibody drug conjugatesSTEMCENTRX INC·Filed 2016·Granted May 31, 2016·10 cites·30 claims
- 1696US9353182B2Anti-DLL3 antibodiesSTEMCENTRX INC·Filed 2015·Granted May 31, 2016·10 cites·21 claims
- 1796US9334318B1Multivalent DLL3 antibodiesSTEMCENTRX INC·Filed 2016·Granted May 10, 2016·11 cites·28 claims
- 1896US9155803B1Anti-DLL3 antibody drug conjugates and methods of useSTEMCENTRX INC·Filed 2015·Granted Oct 13, 2015·10 cites·30 claims
- 1996US9133271B1Anti-DLL3 antibody drug conjugates and methods of useSTEMCENTRX INC·Filed 2015·Granted Sep 15, 2015·10 cites·30 claims
- 2096US9089617B2Anti-DLL3 antibody drug conjugatesSTEM CENTRX INC·Filed 2014·Granted Jul 28, 2015·13 cites·30 claims
- 2195US10137204B2Anti-DLL3 antibody drug conjugates for treating cancerABBVIE STEMCENTRX LLC·Filed 2016·Granted Nov 27, 2018·8 cites·33 claims
- 2295US9486537B2Anti-DLL3 antibody drug conjugatesSTEMCENTRX INC·Filed 2016·Granted Nov 8, 2016·9 cites·22 claims
- 2395US9480757B2Anti-DLL3 antibody drug conjugatesSTEMCENTRX INC·Filed 2016·Granted Nov 1, 2016·9 cites·29 claims
- 2495US9107961B2Anti-DLL3 antibody drug conjugates for treating cancerSTEM CENTRX INC·Filed 2014·Granted Aug 18, 2015·11 cites·30 claims
- 2595US9089616B2Anti-DLL3 antibody drug conjugates and methods of useSTEM CENTRX INC·Filed 2014·Granted Jul 28, 2015·10 cites·30 claims
- 2694US9090683B2Methods of detection, diagnosis, and monitoring using anti-DLL3 antibodiesSTEM CENTRX INC·Filed 2014·Granted Jul 28, 2015·10 cites·30 claims
- 2790US9345784B1Methods of delivering DLL3 antibody drug conjugatesSTEMCENTRX INC·Filed 2016·Granted May 24, 2016·3 cites·30 claims
- 2889US9676850B2Anti SEZ6 antibodies and methods of useSTEM CENTRX INC·Filed 2013·Granted Jun 13, 2017·10 cites·12 claims
- 2989US9173959B1Anti-DLL3 antibody drug conjugatesSTEMCENTRX INC·Filed 2015·Granted Nov 3, 2015·3 cites·30 claims
- 3088US9481727B2Anti-DLL3 antibody drug conjugatesSTEMCENTRX INC·Filed 2016·Granted Nov 1, 2016·2 cites·26 claims
- 3183US10308721B2Anti-DLL3 antibodies and drug conjugates for use in melanomaABBVIE STEMCENTRX LLC·Filed 2015·Granted Jun 4, 2019·7 cites·28 claims
- 3280US10934359B2Anti-BMPR1B antibodies and methods of useABBVIE STEMCENTRX LLC·Filed 2017·Granted Mar 2, 2021·3 cites·9 claims
- 3380US10053511B2Anti-claudin antibodies and methods of useABBVIE STEMCENTRX LLC·Filed 2014·Granted Aug 21, 2018·5 cites·55 claims
- 3480US9993566B2SEZ6 modulators and methods of useABBVIE STEMCENTRX LLC·Filed 2014·Granted Jun 12, 2018·4 cites·41 claims
- 3577US10533051B2Anti SEZ6 antibodies and methods of useABBVIE STEMCENTRX LLC·Filed 2017·Granted Jan 14, 2020·1 cites·17 claims
- 3677US2019247510A1Dll3 modulators and methods of useABBVIE STEMCENTRX LLC·Filed 2019·Application pending·0 cites
- 3776US10428156B2Anti-MFI2 antibodies and methods of useABBVIE STEMCENTRX LLC·Filed 2015·Granted Oct 1, 2019·3 cites·32 claims
- 3875US2019046656A1Dll3 modulators and methods of useABBVIE STEMCENTRX LLC·Filed 2018·Application pending·0 cites
- 3971US10189910B2Anti-DPEP3 antibodies and methods of useABBVIE STEMCENTRX LLC·Filed 2016·Granted Jan 29, 2019·1 cites·38 claims
- 4071US9777071B2Anti-DPEP3 antibodies and methods of useABBVIE STEMCENTRX LLC·Filed 2016·Granted Oct 3, 2017·1 cites·15 claims
- 4167US2020181256A1Anti sez6 antibodies and methods of useABBVIE STEMCENTRX LLC·Filed 2019·Application pending·0 cites
- 4254US2021261670A1Novel anti-bmpr1b antibodies and methods of useABBVIE STEMCENTRX LLC·Filed 2021·Application pending·0 cites
- 4352US2019225685A1Anti-dll3 antibody drug conjugates and methods of useABBVIE STEMCENTRX LLC·Filed 2019·Application pending·0 cites
- 4449US2019077876A1Novel anti-claudin antibodies and methods of useABBVIE STEMCENTRX LLC·Filed 2018·Application pending·0 cites
- 4549US2019022241A1Novel sez6 modulators and methods of useABBVIE STEMCENTRX LLC·Filed 2018·Application pending·0 cites
- 4644US2019201542A1Anti-dll3 drug conjugates for treating tumors at risk of neuroendocrine transitionABBVIE STEMCENTRX LLC·Filed 2017·Application pending·0 cites
- 4741US2019016812A1Novel anti-tnfsf9 antibodies and methods of useABBVIE STEMCENTRX LLC·Filed 2016·Application pending·0 cites
- 4838US2019194319A1Anti-ascl1 antibodies and methods of useABBVIE STEMCENTRX LLC·Filed 2017·Application pending·0 cites
- 4937US2019127476A1Novel anti-tnfrsf21 antibodies and methods of useABBVIE STEMCENTRX LLC·Filed 2017·Application pending·0 cites
- 5035US2019022242A1Novel anti-mmp16 antibodies and methods of useABBVIE STEMCENTRX LLC·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Laura Saunders files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →